{
    "nctId": "NCT05979220",
    "briefTitle": "Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy",
    "officialTitle": "A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 178,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.\n2. Age: 18 - 75 years old\n3. Eastern Cooperative Oncology Group performance status (ECOG PS)=0\\~1\n4. Functions of liver and kidney is normal\n5. Agreed to take contraceptive measures during treatment\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of HER2 positive disease.\n2. Central nervous system metastasis\n3. Patients who received prior treatment with any CDK4/6 inhibitor.\n4. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \\> 2), or ventricular arrhythmia which need medical intervention\uff1b\n5. Researchers believe that is not suitable for the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}